Production issues could put a damper on Novo Nordisk's 2022
Novo Nordisk’s supply issues of its obesity drug, Wegovy, are blurring the company’s growth outlook and creating doubts about its 2022 guidance, reports Danish media Børsen.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Analysts and investors are concerned about Novo Nordisk’s current production problems with obesity drug Wegovy, which have arisen due to issues at the Danish pharmaceutical company’s contract manufacturer, Catalent, reports Danish business media Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Catalent behind Novo Nordisk's supply issues, says media
For subscribers
